Breaking News, Trials & Filings

Pfizer Initiates Pediatric Phase 2/3 Study of Oral COVID Treatment

PAXLOVID is the first oral therapy specifically designed to combat COVID-19 to be evaluated in a pediatric clinical study.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer initiated a Phase 2/3 study, EPIC-PEDS (Evaluation of Protease Inhibition for COVID-19 in Pediatric Patients), to evaluate the safety, pharmacokinetics, and efficacy of Pfizer’s PAXLOVID (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) in non-hospitalized, symptomatic, pediatric participants with confirmed COVID-19 who are at risk of progression to severe disease.   The Phase 2/3 trial is an open-label, multi-center, single-arm study in approximately 140 pediatric participants...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters